

Neurology Research Areas of Interest

Neuromyelitis Optica Spectrum Disorder (NMOSD)

- Real-world effectiveness and safety of ravulizumab across AQP4(+) NMOSD treatment algorithm including special populations
- Clinical benefit of ravulizumab in AQP4(+) NMOSD patients with suboptimal response to other disease modifying therapies-efficacy and safety evaluation.
- Implementation and outcomes of risk mitigation strategies on initiation of ravulizumab in the real-world for AQP4(+) NMOSD management
- Clinical benefit of ravulizumab as assessed by emerging biomarkers in AQP4(+) NMOSD excluding GFAP and NFL.

Out of Scope

- Clinical comparative studies with other disease modifying treatments
- Pre-clinical studies

Generalized Myasthenia Gravis (gMG)

- Effectiveness and safety of earlier treatment with complement inhibitors in patients with gMG
- Effectiveness and safety of switching from other approved gMG therapies to complement inhibitors
- Assessing MG disease status, with novel clinical, patient-centric or composite outcomes
- Digital and/or physiologic biomarkers to identify gMG patients who may benefit the most from complement inhibitor treatment

Out of Scope

- Clinical comparative studies with other disease modifying treatments